Mirum Pharmaceuticals Inc. (MIRM)
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Clinical Results in Primary Sclerosing Cholangitis and Hepatitis Delta Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Clinical Results in Primary Sclerosing Cholangitis and Hepatitis Delta Transcript
Will Livmarli Continue to Aid Mirum's Top Line in Q1 Earnings?
MIRM heads into Q1 earnings with Livmarli sales in focus after 69% year-over-year growth in 2025. Bile acid products broaden revenue momentum.
Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last?
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Is Mirum Pharmaceuticals (MIRM) Down 3.6% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli
MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.
Mirum Completes Enrollment & Screening in Liver Disease Studies
MIRM completes enrollment in phase III AZURE-1 and screening in AZURE-4 for brelovitug in HDV, with top-line data expected in the second half of 2026.
Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
MIRM posts Q4 loss. Revenues jump 50% on strong Livmarli and bile acid drug sales, topping estimates in Q4 2025 and lifting shares.
Mirum Pharmaceuticals (MIRM) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Mirum Pharmaceuticals (MIRM) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.02. This compares to a loss of $0.49 per share a year ago.
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Mirum Pharmaceuticals on a Strong Path to Profitability?
Mirum Pharmaceuticals was profitable in the third quarter. However, top-line growth for the midcap biotech will slow this year.
